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A B S T R A C T   
Background: Cancer patients, with an incidence of more than 18 million new cases per year, may constitute a 
significant portion of the COVID-19 infected population. In the pandemic situation, these patients are considered 
highly vulnerable to infectious complications due to their immunocompromised state. 
Material & Methods: In this retrospective case series, the documents of solid cancer patients infected by SARS- 
CoV-2, hospitalized in Shariati hospital between 20 February and 20 April 2020, were evaluated. The diag-
nosis of COVID-19 was based on laboratory-confirmed COVID-19 and/or features of chest CT scan highly sug-
gestive for SARS-CoV-2. 
Results: A total of 33 COVID-19-infected cancer patients were included. Mean age was 63.9 years, and 54.5% of 
the patients were male. LDH level was significantly higher (1487.5 ± 1392.8 vs. 932.3 ± 324.7 U/L, P-val-
ue=0.016) and also serum albumin was significantly lower in non-survivors (3.6 ± 0.5 vs. 2.9 ± 0.6 g/dL, p- 
value=0.03). Among 16 patients with stage IV cancer, thirteen patients died, which was significantly higher 
compared to stage I-III cancer patients (81.3% vs. 18.8% P-value= <0.001). In terms of developing complica-
tions, sepsis, invasive ventilation and mortality was significantly higher in patients who received cytotoxic 
chemotherapy within the last 14 days. 
Conclusion: In this study, we showed that the mortality rate among cancer patients affected by COVID-19 was 
higher than general population and this rate has a significant correlation with factors including the stage of the 
disease, the type of cancer, the activity of cancer and finally receiving cytotoxic chemotherapy within 14 days 
before diagnosis of COVID-19.    
Abbreviations and Symbols 
COVID-19: Coronavirus Disease 2019 
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2 
RT-PCR: Reverse transcription-polymerase chain reaction 
ICU: Intensive care unit 
COPD: Chronic obstructive pulmonary disease 
ARDS: Acute respiratory distress syndrome 
AMI: Acute myocardial infarction 
PTE: Pulmonary thromboembolism 
Introduction 
The outbreak of coronavirus disease 2019 (COVID-19) within the 
viral background of severe acute respiratory syndrome coronavirus 2 
(SARS-COV-2), which is a novel single-stranded enveloped RNA virus, 
was first reported in the city of Wuhan, China in December 2019 [1]. 
Until now, six coronaviruses have been known to infect humans, 
including two aggressive strains, severe acute respiratory syndrome 
(SARS) and Middle East respiratory syndrome (MERS), with a fatality 
rate of about 10% and 34%, respectively [2, 3]. However, the fatality 
rate of SARS-COV-2 in China, has been reported to be 2.3% with a high 
transmission rate [4]. Accordingly, World Health Organization (WHO) 
declared COVID-19 as a public health emergency with international 
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concern. As of June 2020, this virus has affected more than 216 coun-
tries, infecting more than 8242,999 individuals and causing over 445, 
535 deaths [5]. 
Cancer patients, with an incidence of more than 18 million new cases 
per year, may constitute a significant portion of the COVID-19 infected 
population [6]. In the pandemic situation, these patients are considered 
highly vulnerable to infectious complications due to their immuno-
compromised state [7]. Moreover, advanced age, poor functional status 
and frequent hospital visits, could increase the morbidity and mortality 
of COVID-19 in cancer patients [8]. 
Therefore, it is imperative to clear the clinical course and the out-
comes of cancer patients infected by COVID-19, and the safety of 
receiving antineoplastic treatments as usual in the outbreak period. In 
this retrospective case study, we presented the clinical data, laboratory 
features and outcomes of hospitalized COVID-19 cancer patients. 
Material and methods 
Study design and participants 
In this retrospective case series, the documents of solid cancer pa-
tients infected by SARS-CoV-2, hospitalized in Shariati hospital (a ter-
tiary care referral center designated for COVID-19 patients, affiliated by 
Tehran University of Medical Sciences) between 20 February and 20 
April 2020, were evaluated. This study was by the Ethics committee of 
Tehran University of Medical Sciences. All patients filled an informed 
written consent form. 
The diagnosis of COVID-19 was based on a positive real-time fluo-
rescence reverse transcription-polymerase chain reaction (RT-PCR) for 
SARS-CoV-2 nucleic acids from nasal and/or pharyngeal specimens and/ 
or features of chest CT scan highly suggestive for SARS-CoV-2 (i.e. the 
presence of ground glass opacities (GGO), typically with a peripheral 
and subpleural distribution)[9]. Patients were hospitalized according to 
the following criteria: prolonged fever (>5 days), respiratory distress 
(respiratory rate >24 breaths/min), hypoxia (oxygen saturation ≤94% 
at rest) and hypotension (systolic blood pressure ≤90 mmHg) [2]. 
Severe clinical events were defined as intensive care unit (ICU) 
admission, mechanical ventilation necessity, or death[10]. Clinical 
features, laboratory findings, and chest computed tomography (CT) 
images were collected. Moreover, history of antineoplastic treatments 
and comorbidities of the patients, including chronic obstructive pul-
monary disease (COPD), hypertension, and diabetes mellitus (DM), were 
recorded. 
Statistical analysis 
For descriptive analysis, continuous variables were presented as the 
mean with standard deviation as appropriate. Categorical variables are 
presented as number (%). The Shapiro Wilk test was used to test the 
normality of data distribution. The χ2 test or Fisher’s exact test was used 
for analysis of categorical data, and the Student t-test or Mann-Whitney 
U test were used for continuous data. All statistical analysis was carried 
out using SPSS Statistics version 26.0 (IBM, New York, NY). A two-side 
P-value <0.05 was considered statistically significant. 
Results 
Between 20 February to 20 April 2020, out of a total of 580 patients 
admitted in specialized ward for COVID-19 of Shariati hospital, 33 pa-
tients had a history of solid cancers (5.68%). Among these, 11 patients 
had a positive RT-PCR for SARS-CoV-2 and 22 patients had highly 
suggestive chest CT scan findings in favor of SARS-CoV-2 but negative 
RT-PCR . The mean age of the patients was 63.9 years, and 54.5% of the 
patients were males. Age and sex of the patients did not correlate with 
mortality (P-value=0.312 and 0.22 respectively). Demographic and 
clinical features of these patients are summarised in Table 1. 
Regarding to laboratory findings, blood count results, at the time of 
admission showed anemia (i.e. Hb<12 mg/dl) in 26 (78.78%) patients, 
lymphocytopenia (absolute lymphocyte count <1000/microL) in 23 
(69.69%) and thrombocytopenia (platelet count Less than 150,000/ 
microL) in 14 (42.42%) patients. Mean Neutrophil-to-lymphocyte ratio 
(NLR) was 12.9. Elevated erythrocyte sedimentation rate (i.e., > 30 
mm/hour) was found in 27 patients (81.81%), high C-reactive protein (i. 
e., > 10 mg/L) levels in 31 patients (93.93%), high levels of lactate 
dehydrogenase (i.e., > 280 unit/L) in 30 patients (90.90%) and low 
levels of serum albumin (i.e., < 3.5 g/dl) in 29 patients (87.87%). 
There was no difference in COVID-19 symptoms, lymphocytopenia, 
thrombocytopenia between survivors and non-survivors cancer patients. 
However, LDH level was significantly higher (7170±2077 vs. 932.3 ±
324.7 U/L, P-value=0.016) and also serum albumin was significantly 
lower in non-survivors (3.6 ± 0.5 vs. 2.9 ± 0.6 g/dL, p-value=0.03). 
Between two survivors and non-survivors groups PLR (817±2024 vs. 
343±412) and NLR (10.9 ± 9.5 vs.15±13.7, respectively) were not 
significantly different (p-value>0.05). 
The mean length of hospitalization was 7.7 days (range 1.0–30.0) 
and the mean time from the symptoms onset to admission in COVID-19 
unit was 4.34 days (range 0–14.0 days). 
Mortality rate was significantly higher in 18 patients who received 
cytotoxic chemotherapy within the last 14 days (72% vs. 20%, P-value: 
0.03) and they had also significantly shorter mean time from admission 
to death compared with 15 patients who undergone cancer treatment 
more than two weeks before their admission due to COVID-19 or not 
given cytotoxic chemotherapy within the last 14 days (5.62±4.7 days 
Table 1 
Demographic and laboratory data in the patients.   




N = 33 N = 17 N = 16 
Age, years 63.9 ±
11.98 
66.9 ± 12.8 60.7 ± 10.5 >
0.05 
Interval from fever onset 
to dyspnea onset (day) 
4.1 ± 4.1 4.69 ± 3.75 3 ± 4.86 >
0.05 
Symptoms and signs at 
on admission     
Fever 20 (60.6) 13 (76.5) 7 (43.8) >
0.05 
Cough 16 (48.5) 9 (52.9) 7 (43.8) >
0.05 
Serum Biomarkers     
WBC count, 103/μL 10.2 ± 7.8 10.1 ± 8.1 10.3 ± 7.6 >
0.05 
Hb, g/dl 11.9 ± 3.1 12.1 ± 3.3 11.8 ± 3. >
0.05 
RDW 14.7 ± 2.8 14.6 ± 2.5 14.9 ± 2.9 >
0.05 
Neutrophil × 109/L 8.4 ± 7.3 7.8 ± 7.9 8.9 ± 6.8 >
0.05 
Lymphocyte × 109/L 0.87±0.82 0.88±0.71 0.86±0.94 >
0.05 





12.9 ± 11.7 10.9 ± 9.5 15±13.7 >
0.05 
Lymphocyte-to-C- 


















Serum Albumin (g/dL) 3.2 ± 0.7 3.6 ± 0.5 2.9 ± 0.6 0.03 





ESR (mm/hr) 69.1 ± 34.9 64.1 ± 34.5 77.4 ± 35.7 >
0.05 
CRP (mg/L) 90.2 ± 58.7 97.6 ± 68.4 82.3 ± 46.8 >
0.05 
Data in are presented as No. (%) or Mean ± SD. 
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vs18.5 ± 16.2 days P-value: 0.02). 
In terms of developing complications, although sepsis was signifi-
cantly higher in patients who received cytotoxic chemotherapy within 
the last 14 days (50% vs. 13% P-value: 0.026), occurrence of acute 
respiratory distress syndrome (ARDS), acute myocardial infarction 
(AMI) and pulmonary thromboembolism (PTE) were not significantly 
different between the two groups(P-value>0.05) (Fig. 1). 
The most frequent cancers were breast cancer (n = 6, 18.2%), colon 
cancer (n = 6, 18.2%) and gastric cancer (n = 6, 18.2%). Among them, 
five patients had a history of pulmonary metastasis (table 2). Moreover, 
four patients (12.12%) had a primary diagnosis of lung cancer. Type of 
the cancer did not correlate with mortality (P-value=0.5). However, the 
mortality rate was significantly higher in patients with a history of lung 
cancer or metastasis to lung compared to other types of cancer (77% vs. 
37% P-value = 0.039). 
Out of 33 cancer patients, in 16 cases (48.48%) the cancer was in 
stage IV, at the time of diagnosis. Among 16 patients with stage IV 
cancer, thirteen patients died, which was significantly higher compared 
to stage I-III cancer patients (81.3% vs 18.8% P-value <0.001). 
It should be noted that 5 patients (15.15%) developed COVID-19 
during antitumour therapy in the hospital (nosocomial SARS-COV-2 
infection), but none of them experienced mortality. 
In addition to cancer, the most frequent coexisting chronic diseases 
were cardiovascular diseases (n = 9,27.3%) and diabetes mellitus (n =
8,24.2%). Associated comorbidities did not significantly increase mor-
tality in this patient series (P-value >0.05). 
The most common symptoms on admission were dyspnea (n = 30, 
90.9%), followed by fever (n = 20, 60.6%), dry cough (n = 16, 48.5%) 
and gastrointestinal symptoms (n = 11, 33.3%). The initiating symptom 
did not correlate with mortality (P-value>0.05). 
Out of the 33 hospitalized patients, 29 (87.9%) received oxygen 
therapy, 3 (9.1%) received non-invasive ventilation (NIV) and 16 
(48.5%) patients received invasive ventilation (IV). The median dura-
tion of NIV and IV were 3 days (range 1.0–8.0) and 8 days (range 
0.0–14.0), respectively. Fifteen patients (45.5%) were admitted in 
intensive care unit (ICU). The most common complication was acute 
respiratory distress syndrome (n = 9; 27.3%), followed by sepsis and 
septic shock (n = 11; 33%) and pulmonary thromboembolism (n = 1), 
respectively. In comparison of severe events between the patients who 
received cytotoxic chemotherapy within 14 days and other patients, 
sepsis and IV were significantly higher (Fig. 1). Hydroxychloroquine 
alone was administered in 5 patients and combined with antiviral agents 
such as lopinavir/ritonavir, ribavirin and oseltamivir in 28 patients. 
Corticosteroids were administered in 15 patients, mostly in whom suf-
fered from severe events. A total of 17 (51.5%) patients were discharged 
from the hospital, with a mean hospital stay of 7.5 days (range 5.0–18.0) 
and 16 patients (48.8%) died with a mean interval of 7.33 days from 
admission to death. 
In this study, there was no significant difference between the two 
groups of positive and negative SARS-CoV-2 RT-PCR regarding their sex, Fig. 1. comparison between covid-19 patients who received cytotoxic chemo-
therapy within the last 14 days & more than 14 days. 
Table 2 
Clinical features in survivors vs. non-survivors.   




N = 33 N = 17 N = 16  
Mean age ± SD 63.9 ±
11.98 




Tumor diagnosis     
Lung cancer 4 (12.1) 2 (11.8) 2 (11.8) >
0.05 
Breast cancer 6 (18.2) 3 (17.6) 3 (18.8) >
0.05 
Cholangiocarcinoma 1 (3) 0 (0) 1 (6.3) >
0.05 
Colon cancer 6 (18.2) 4 (23.5) 2 (12.5) >
0.05 
Ovarian cancer 3 (9.1) 1 (5.9) 2 (12.5) >
0.05 
Pancreas cancer 2 (6.1) 0 2 (12.5) >
0.05 
Prostate cancer 3 (9.1) 1 (5.9) 2 (12.5) >
0.05 
Stomach cancer 6 (18.2) 5 (29.4) 1 (6.3) >
0.05 
Testis cancer 2 (6.1) 1 (5.9) 1 (6.3) >
0.05 
Tumor stage     
Stage I/II/III 17 (51.5) 14 (82.4) 3 (18.8) <
0.001 
Stage IV 16 (48.5) 3 (17.6) 13 (81.3)  
History of prior treatment    >
0.05 
Surgery a 3 (9.1) 2 (11.8) 1 (6.3) >
0.05 
Chemo/Radiotherapy a 26 (78.8) 12 (70.6) 14 (87.5) >
0.05 
Hormone Therapy a 2 (6.1) 2 (11.8) 0 >
0.05 
Comorbidities     
Chronic cardiovascular and 
cerebrovascular disease 
(including hypertension and 
coronary heart disease) 
9 (27.3) 3 (17.6) 6 (37.5) >
0.05 
Diabetes 8 (24.2) 5 (29.4) 3 (18.8) >
0.05 
Chronic pulmonary disease 
(including chronic 
obstructive pulmonary 
disease and asthma) 
5 (15.2) 4 (23.5) 1 (6.3) >
0.05 
Chronic liver disease 
(including chronic hepatitis 
B and cirrhosis) 
1 (3) 0 (0) 1 (6.3) >
0.05 
cytotoxic chemotherapy 











Symptoms and signs at on 
admission     
Fever 20 (60.6) 13 (76.5) 7 (43.8) >
0.05 
Cough 16 (48.5) 9 (52.9) 7 (43.8) >
0.05 
Fatigue 15 (45.5) 7 (41.2) 8 (50) >
0.05 
Dyspnea 30 (90.9) 0 (0) 13 (81.3) >
0.05 
Myalgia 5 (15.2) 3 (17.6) 2 (12.5) >
0.05 
GI symptom 11 (33.3) 6 (35.3) 5 (31.3) >
0.05 
Data in are presented as No. (%) or Mean ± SD. 
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age, cancer type, mean Hb concentration, Platelet count, lymphocyte 
count, serum albumin level, ESR and CRP titer or other laboratory 
findings and also in terms of clinical symptoms and coexisting (Table 3). 
It was also shown that in terms of the mortality rate, there was no 
significant difference between the two groups of positive and negative 
SARS-CoV-2 RT-PCR (P-value=0.3). 
Discussion 
The outbreak of COVID-19 is of international concern and as in other 
infectious diseases, people with compromised immune systems 
including the many people with cancer and many more cancer survivors 
are at increased risk for COVID-19 [11]. 
Fear and anxiety over the outbreak of COVID-19 have led to a major 
shift in the provision of cancer care services, with hospitals reducing 
patient visits and conducting telemedicine specially for breast cancer, 
colorectal cancer and gynecological cancer [12]. 
Wang et al. have reported that the proportion of patients with cancer 
histories has been higher in a cohort with COVID-19 than in the general 
population in China, and that the patients with cancer were more likely 
to develop COVID-19 [13]. In our study, 8.1% of the total hospitalized 
COVID-19 patients had cancer, out of which 48.5% passed away. This 
rate of mortality was higher than what was reported by Kuderer et al. 
and the Zhang et al. (13% and 28.6%, respectively) [14,15]. This could 
be caused by due to the fact that in our hospital patients were admitted 
according to a strict national guideline and so the mortality rate was 
higher among all admitted patients. 
The findings in this study showed that the most common symptom in 
hospitalized patients was dyspnea. In general population with COVID- 
19, fever was known to be the most common symptom, which could 
be due to the absence of feverish reactions in patients with immune 
system deficiency. On the other hand, 33.3% of our patients suffered 
from sepsis and septic shock, which also could be in line for immune 
deficiency. 
Among our cancer patients, those with lung cancer or those with lung 
metastasis due to non-pulmonary cancers showed a higher mortality rate 
which could be instigated by a decrease in the lung’s functional capacity 
in these patients. This finding was similar to the report by Zhang et al. 
[14]. study. Dai et al. [6]. also showed that the mortality rate in 
COVID-19 patients with lung cancer was higher than other cancers and 
that the stage of cancer had a direct correlation with mortality. In 
contrast, Lee study[16] reported no increased mortality rate in patients 
with lung cancer, compared with the remaining population with cancer 
and COVID-19, suggesting that patients with lung cancer are not a 
specifically susceptible group. 
In our series, in patients with stage IV cancer, mortality and severe 
events were observed more frequently compared those with stage I-III. 
However, Zhang et al. found no significant correlation between the rate 
of severe events and the stage of cancer [14]. In terms of life-threatening 
complications, the rate of ARDS in our patients was higher than in the 
meta-analysis reported by Hu et al. [17]. 
We found that the mortality rate was significantly higher among the 
patients with active cancer who had undergone cytotoxic chemotherapy 
less than 14 days prior to being admitted due to COVID-19, in com-
parison with the patients who did not have an active cancer and were 
not on recent cytotoxic therapies. This finding is similar to the report by 
Zhang et al. [14]. However, Kuderer et al. [15]. found no significant 
difference between undergoing cytotoxic chemotherapy within 30 days 
prior to COVID-19 diagnosis and its consequential mortality rate [15]. 
The results of our study contradict Lee study[18] that found mortality 
from COVID-19 in cancer patients on cytotoxic chemotherapy or other 
anticancer treatment are similar with those not on active treatment. 
Regarding to the previously conducted studies which reported the 
sensitivity of chest CT scan for diagnosis of COVID-19 to be 97% [19], 
we included the cancer patients who had negative RT-PCR for COVID-19 
but with highly suggestive chest CT scan findings, in our study. There 
was no significant difference between the demographic features of these 
patients and those with positive RT-PCR. Moreover, no difference was 
observed in terms of outcomes and mortality, except that the rate of 
ARDS and the need for invasive mechanical ventilation, which were 
significantly higher in former group, probably due to the primary pul-
monary involvement in these patients. Considering the mentioned 
findings, one can conclude that the in COVID-19 suspected cancer pa-
tients, therapeutic measures should be initiated promptly, regardless of 
RT-PCR results. 
In our study, 84.4% and 45.5% of the patients were prescribed at 
least one antiviral agent and dexamethasone, respectively in early phase 
of pandemic. However, currently there is no drug that has proven to be 
effective against SARS-CoV-2. 
Results of the SOLIDARITY trial on repurposed antivirals had shown 
that these agents had little or no effect on hospitalized patients with 
Covid-19, as indicated by overall mortality, initiation of ventilation, and 
duration of hospital stay [20]. 
Systemic steroids remain controversial in the treatment of viral 
pneumonia. Recent study by the RECOVERY Collaborative Group 
showed the use of dexamethasone has protective effect among moderate 
to severe covid-19 patients who were receiving either invasive me-
chanical ventilation or oxygen alone [21]. 
Knowledge from these studies and others like them, had since 
informed the management of COVID-19 resulting in changes in the care 
of patients and possibly their outcomes. 
This study evaluated the clinical futures and outcome of cancer pa-
tients affected by COVID-19 during early phase the current − 19 
pandemic wherein healthcare teams grappled with the challenge of 
managing this infection. The result of this study including the clinical 
feature, treatment and the outcome of the patients could be compared 
with studies conducted in next phases of COVID-19 pandemic to better 
understand the difference between these phases. 
Conclusion 
In this study, we showed that the mortality rate among cancer pa-
tients affected by COVID-19 was higher than general population and this 
rate has a significant correlation with factors such as the stage of the 
disease, the type of cancer, the activity of cancer and finally receiving 
Table 3 







Age, years 59.8±.16.9 65.9±.8.3 >0.05 
Sex, n (%)    
Male 7 (63.6) 11 (50) >0.05 
Female 4 (36.4) 11 (50)  
Serum Biomarker    
ESR(mm/hr) 66.8 ± 37.1 70.3 ± 34.6 >0.05 
CRP (mg/L) 73 ± 35.7 98.8 ± 66.4 >0.05 
NLR 13.5 ± 13.4 12.6 ± 11.1 >0.05 
LCR 98.9 ± 265.1 14.9 ± 23.8 >0.05 
Albumin (g/dL) 3.2 ± 0.65 3.3 ± 0.75 >0.05 
LDH (U/L) 1586 ± 1319 1438 ± 1455 >0.05 
Admit to Death, days 4.2 ± 2.6 8.4 ± 8.6 >0.05 
Length of hospitalization, 
days 
5.45± 3.2 8.8 ± 6.9 >0.05 
Symptom to hospital, day 3.2 ± 4.3 4.9 ± 4.1 >0.05 
Severe event, n (%)    
ARDS 1(9.1) 8(36.4) >0.05 
Sepsis 2(18.2) 9(40.9) >0.05 
Invasive Ventilation 4(36.4) 12(54.5) >0.05 
ICU Admission 4(36.4) 11(50) >0.05 
Death 4(36.4) 12(54.5) >0.05 
Data in are presented as No. (%) or Mean ± SD. 
NLR: Neutrophil to Lymphocyte ratio, CRP: C - reactive protein, ESR: Erythro-
cyte Sedimentation Rate, LCR: Lymphocyte to CRP Ratio. ARDS, acute respira-
tory distress syndrome. 
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cytotoxic chemotherapy within 14 days before diagnosis of COVID-19. 
We also showed that the outcome of cancer patients with positive RT- 
PCR for COVID-19 is similar to those with negative RT-PCR with high-
ly suggestive chest CT scan findings. 
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